AstraZeneca began trading on the New York Stock Exchange on Monday, February 2, 2026, marking a significant shift in the pharmaceutical giant’s U.S. market strategy as it ended its American Depositary Shares program on Nasdaq. The UK-based drugmaker delisted its
AstraZeneca has announced a $15 billion investment in China through 2030 to expand medicines manufacturing and research and development capabilities, with a strategic focus on cell therapies and radioconjugates. The announcement came on Thursday, 29th January during UK Prime Minister
“We really have a tough target of cutting emissions by 50% by 2030—we need to understand the right path with our suppliers” Nataša Vidmar, SVP and Chief Procurement Officer at AstraZeneca, delivered a clear message at the PSCI Decarbonization Summit:
AstraZeneca has become the second major pharmaceutical manufacturer to sign a “most favored nation” pricing agreement with the Trump administration, committing to match the lowest drug prices offered in developed nations for Medicaid programs and newly launched products. President Donald
“The healthcare industry is responsible for 5% of global emissions, which is more than aviation,” says Robert Williams Director of Sustainable Procurement at AstraZeneca. As Vice Chair of the Pharmaceutical Supply Chain Initiative (PSCI), he regularly engages with a wide
AstraZeneca has announced plans to build a $1.5 billion manufacturing facility in Singapore for antibody drug conjugates (ADCs). This greenfield facility, supported by the Singapore Economic Development Board (EDB), will be the company’s first end-to-end ADC production site, fully incorporating
